About: Toni K Choueiri

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Toni K Choueiri Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

American medical oncologist

Attributes	Values
rdf:type	Item
owl:sameAs	Toni K Choueiri
description	ikertzailea (eu) 연구원 (ko) wetenschapper (nl) дослідник (uk) American medical oncologist (en)
rdfs:label	Toni K Choueiri (en) Toni K Choueiri (nl)
skos:prefLabel	Toni K Choueiri (en) Toni K Choueiri (nl)
name	Toni K Choueiri (en) Toni K Choueiri (nl)
image	wds:Q88414622-10124583-A09B-462B-AEA3-9AF2FB8356EA
instance of	wds:Q88414622-91472529-CC81-4416-99B1-53A4F84D0F9C
image
instance of	Homo sapiens
Google Knowledge Graph ID	wds:Q88414622-71CC8DFC-10BD-45B8-BCF4-6A1218E18679
Google Knowledge Graph ID	http://g.co/kg/g/11byd7z4jn
Google Knowledge Graph ID	/g/11byd7z4jn
Google Scholar author ID	wds:Q88414622-a525312f-4bee-4a8c-b9eb-831fc9b1b37c
Google Scholar author ID	LHu6RiAAAAAJ
skos:altLabel	Toni Choueiri (en)
occupation	wds:Q88414622-FE8D5BF6-E0AA-488F-9176-07F7D3846DA2
employer	wds:Q88414622-ED4048F3-7F9A-4884-8FAC-0D3F436C5C71
sex or gender	wds:Q88414622-52a95a1f-450b-98f2-ef9d-2edad27e8da7
ISNI	wds:Q88414622-0f65d67a-4feb-4659-1b5b-94581b98fb29
VIAF ID	wds:Q88414622-2e560fbf-4d2e-3393-bf82-9b79aec02feb
Library of Congress authority ID	wds:Q88414622-e9965c6c-4c59-7128-9e80-eef7cd96b3b9
WorldCat Identities ID (superseded)	wds:Q88414622-f8ca9f8e-458b-a6f0-a402-4afe39125016
VIAF ID	http://viaf.org/viaf/187046351
Library of Congress authority ID	http://id.loc.gov/authorities/names/nb2011023688
occupation	researcher
employer	Dana–Farber Cancer Institute
sex or gender	male
ISNI	0000000351047477
VIAF ID	187046351
Library of Congress authority ID	nb2011023688
WorldCat Identities ID (superseded)	lccn-nb2011023688
ORCID iD	wds:Q88414622-45317F03-13DE-42CE-A714-DC046709A388
ORCID iD	https://orcid.org/0000-0002-9201-3217
ORCID iD	0000-0002-9201-3217
is about of	Toni K Choueiri https://www.wikidata.org/wiki/Special:EntityData/Q88414622 Toni Choueiri
is author of	Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men With High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials Future directions and targeted therapies in bladder cancer Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors NCCN clinical practice guidelines in oncology: kidney cancer Overall survival in renal-cell carcinoma with pazopanib versus sunitinib Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study Phase II study of lenalidomide in patients with metastatic renal cell carcinoma Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC) Kidney cancer, version 3.2015. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma Prospective evaluation of analgesic use and risk of renal cell cancer Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. New therapies for castrate-resistant prostate cancer Metabolic complications with the use of mTOR inhibitors for cancer therapy Pazopanib versus sunitinib in metastatic renal-cell carcinoma External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study Cost implications of the rapid adoption of newer technologies for treating prostate cancer von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941 Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial Association Between Older Age and Increasing Gleason Score Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. ¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software